If ENTB does develop drug cures for inflammatory animal diseases and canine cancer the valuation will be well over $1. Keep in mind that one of Entest's competitors is Aratana Therapeutics(PETX) which has a similar share structure(38M), and has a current share price of $6.43, market cap of $239M. Still a development company. Which allow shows how undervalued ENTB is right now. So if Entest scores on drugs for inflammation(arthritis, other), and cancer this company will have significant value to a big BP.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.